Tuesday, December 03, 2024 3:12:56 PM
Recent MDCX News
- Medicus Pharma reports positive Phase 2 results for SkinJect skin cancer therapy • IH Market News • 03/05/2026 03:01:58 PM
- Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort • GlobeNewswire Inc. • 03/05/2026 12:30:00 PM
- Medicus Pharma To Participate in the 38th Annual Roth Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Medicus Pharma on Bloomberg World • ACCESS Newswire • 02/12/2026 12:30:00 PM
- Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk • GlobeNewswire Inc. • 02/10/2026 12:30:00 PM
- Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony • ACCESS Newswire • 01/23/2026 12:30:00 PM
- Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile • GlobeNewswire Inc. • 01/22/2026 12:30:00 PM
- Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026 • GlobeNewswire Inc. • 01/20/2026 12:30:00 PM
- Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women • GlobeNewswire Inc. • 01/12/2026 12:30:00 PM
- Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates • GlobeNewswire Inc. • 01/05/2026 12:30:00 PM
- Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform • ACCESS Newswire • 12/22/2025 12:30:00 PM
- Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement • ACCESS Newswire • 12/05/2025 08:20:00 PM
- Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President • ACCESS Newswire • 12/01/2025 01:00:00 PM
- Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President • GlobeNewswire Inc. • 12/01/2025 12:30:00 PM
- Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers • GlobeNewswire Inc. • 11/24/2025 01:00:00 PM
- Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin • ACCESS Newswire • 11/17/2025 12:30:00 PM
- Medicus Pharma Ltd. Announces Filing of FDA Commissioner’s National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin • GlobeNewswire Inc. • 11/17/2025 12:30:00 PM
- Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights • ACCESS Newswire • 11/14/2025 10:00:00 PM
- Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin • ACCESS Newswire • 11/13/2025 12:30:00 PM
- BTV Spotlights: Netcoins, Kodiak, Sitka, Kneat, Highland Copper, Northstar Clean Technologies, Mineros, Stillwater, Medicus, & Newcore • Newsfile • 11/10/2025 02:00:00 PM
- Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome • GlobeNewswire Inc. • 10/29/2025 11:30:00 AM
- Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome • ACCESS Newswire • 10/29/2025 11:30:00 AM
- Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin • ACCESS Newswire • 10/22/2025 11:30:00 AM
- Three Biotech Companies Redefining Value Creation Through Dual Strategies • ACCESS Newswire • 10/14/2025 12:22:00 PM
RENI Completes Due Diligence on Target Acquisition; Confirms Strong Asset Base and Operational Performance • RENI • Mar 5, 2026 10:15 AM
BlackStar Engages in Talks with U.S. Senate Banking Committee Team Covering the Digital Asset Market Clarity Act • BEGI • Mar 4, 2026 4:47 PM
ECGI Highlights RezyFi Live Pilot Progress in CEO Interview Update • ECGI • Mar 3, 2026 8:30 AM
Journal of Analytical Toxicology Publishes Peer-Reviewed Validation Study • BLO • Mar 3, 2026 8:18 AM
LaFleur Minerals Announces Positive PEA Results for the Swanson Gold Deposit • LFLRF • Mar 3, 2026 8:00 AM
Invech Holdings Inc. New Management, Enhanced Goals • IVHI • Mar 2, 2026 3:54 PM
